Perceptive Advisors LLC acquired a new position in Ignyta Inc (NASDAQ:RXDX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 30,211 shares of the biopharmaceutical company’s stock, valued at approximately $807,000.
Several other hedge funds have also bought and sold shares of RXDX. Eagle Asset Management Inc. bought a new position in shares of Ignyta in the 4th quarter worth about $60,248,000. Gardner Lewis Asset Management L P bought a new position in shares of Ignyta in the 4th quarter worth about $49,431,000. Alliancebernstein L.P. increased its position in Ignyta by 1,414.3% in the 4th quarter. Alliancebernstein L.P. now owns 1,746,002 shares of the biopharmaceutical company’s stock valued at $46,618,000 after buying an additional 1,630,702 shares in the last quarter. Carillon Tower Advisers Inc. bought a new stake in Ignyta in the 4th quarter valued at about $41,780,000. Finally, Alpine Associates Management Inc. bought a new stake in Ignyta in the 4th quarter valued at about $41,028,000. 72.28% of the stock is owned by hedge funds and other institutional investors.
Shares of Ignyta Inc (RXDX) opened at $26.98 on Tuesday. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.34. Ignyta Inc has a 1-year low of $5.80 and a 1-year high of $27.10. The stock has a market cap of $1,790.00, a price-to-earnings ratio of -9.96 and a beta of 184.87.
A number of analysts recently commented on the company. Zacks Investment Research raised Ignyta from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research report on Wednesday, January 10th. ValuEngine raised Ignyta from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Cantor Fitzgerald reissued a “hold” rating and set a $27.00 price objective on shares of Ignyta in a report on Friday, February 9th. Ladenburg Thalmann Financial Services lowered Ignyta from a “buy” rating to a “neutral” rating in a report on Tuesday, December 26th. Finally, Jefferies Group lowered Ignyta from a “buy” rating to a “hold” rating and set a $27.00 price objective for the company. in a report on Thursday, December 28th. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $27.00.
ILLEGAL ACTIVITY WARNING: This piece was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/03/20/perceptive-advisors-llc-invests-807000-in-ignyta-inc-rxdx-stock.html.
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.